[{"address1": "12790 El Camino Real", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "760 593 4832", "website": "https://ventyxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.", "fullTimeEmployees": 81, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sheila K. Gujrathi M.D.", "age": 54, "title": "Executive Chairperson", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 125000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raju S. Mohan Ph.D.", "age": 66, "title": "Founder, CEO, President & Director", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 979215, "exercisedValue": 0, "unexercisedValue": 5922}, {"maxAge": 1, "name": "Mr. Matthew Richard Moore", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 612510, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark S. Forman M.D., Ph.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 380965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Roy M. Gonzales CPA, M.B.A.", "age": 48, "title": "Senior VP of Finance and Principal Financial & Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John M. Nuss Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 630635, "exercisedValue": 0, "unexercisedValue": 451580}, {"maxAge": 1, "name": "Ms. Snehal  Naik Ph.D.", "title": "Senior VP of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathy  Ogilvie Ph.D.", "title": "Senior VP of Translational & Nonclinical Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rosa  Ferrao", "title": "Senior VP of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.53, "open": 3.62, "dayLow": 3.42, "dayHigh": 3.79, "regularMarketPreviousClose": 3.53, "regularMarketOpen": 3.62, "regularMarketDayLow": 3.42, "regularMarketDayHigh": 3.79, "payoutRatio": 0.0, "beta": 1.011, "forwardPE": -1.6744184, "volume": 1911209, "regularMarketVolume": 1911209, "averageVolume": 982081, "averageVolume10days": 1904830, "averageDailyVolume10Day": 1904830, "bid": 2.68, "ask": 4.41, "bidSize": 2, "askSize": 2, "marketCap": 256710672, "fiftyTwoWeekLow": 0.783, "fiftyTwoWeekHigh": 3.915, "allTimeHigh": 47.251, "allTimeLow": 0.783, "fiftyDayAverage": 2.6853, "twoHundredDayAverage": 2.043115, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 58046664, "profitMargins": 0.0, "floatShares": 53555549, "sharesOutstanding": 71308518, "sharesShort": 4533282, "sharesShortPriorMonth": 4695669, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.0636, "heldPercentInsiders": 0.041100003, "heldPercentInstitutions": 0.68718004, "shortRatio": 10.14, "shortPercentOfFloat": 0.0675, "impliedSharesOutstanding": 71308518, "bookValue": 2.939, "priceToBook": 1.2249064, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -119027000, "trailingEps": -1.66, "forwardEps": -2.15, "enterpriseToEbitda": -0.446, "52WeekChange": 0.6981132, "SandP52WeekChange": 0.17904854, "quoteType": "EQUITY", "currentPrice": 3.6, "targetHighPrice": 21.0, "targetLowPrice": 2.0, "targetMeanPrice": 11.5, "targetMedianPrice": 11.5, "recommendationMean": 1.625, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 208959008, "totalCashPerShare": 2.93, "ebitda": -130108000, "totalDebt": 10295000, "quickRatio": 18.307, "currentRatio": 19.123, "debtToEquity": 4.917, "returnOnAssets": -0.3023, "returnOnEquity": -0.48564997, "freeCashflow": -59710000, "operatingCashflow": -105705000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VTYX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1759535797, "regularMarketTime": 1759521600, "shortName": "Ventyx Biosciences, Inc.", "longName": "Ventyx Biosciences, Inc.", "regularMarketChangePercent": 1.983, "regularMarketPrice": 3.6, "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 982081, "fiftyTwoWeekLowChange": 2.817, "fiftyTwoWeekLowChangePercent": 3.597701, "fiftyTwoWeekRange": "0.783 - 3.915", "fiftyTwoWeekHighChange": -0.31500006, "fiftyTwoWeekHighChangePercent": -0.08045979, "fiftyTwoWeekChangePercent": 69.81132, "earningsTimestampStart": 1762459200, "earningsTimestampEnd": 1762459200, "earningsCallTimestampStart": 1715286600, "earningsCallTimestampEnd": 1715286600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.66, "epsForward": -2.15, "exchange": "NMS", "messageBoardId": "finmb_672535556", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1634823000000, "postMarketChangePercent": -0.299997, "postMarketPrice": 3.5892, "postMarketChange": -0.0107999, "regularMarketChange": 0.0699999, "regularMarketDayRange": "3.42 - 3.79", "epsCurrentYear": -1.67571, "priceEpsCurrentYear": -2.148343, "fiftyDayAverageChange": 0.9146998, "fiftyDayAverageChangePercent": 0.34063223, "twoHundredDayAverageChange": 1.556885, "twoHundredDayAverageChangePercent": 0.7620154, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-21", "averageAnalystRating": "1.6 - Buy", "displayName": "Ventyx Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-10-04"}]